采用PGTseq靶向下一代测序平台进行非整倍体植入前遗传学检测时,初始滋养外胚层活检与胚胎其余部分的一致性率
该盲法前瞻性队列研究对300枚囊胚进行再次活检,评估PGTseq平台初始滋养外胚层活检结果与胚胎其余部分的一致性。整倍体或整条染色体非整倍体结果在再次活检中确认率超过99%,而整条染色体或片段嵌合结果确认率仅为15%-18%,片段非整倍体确认率为56.6%。
要点
- PGTseq平台初始活检为整倍体或整条染色体非整倍体时,与胚胎其余部分高度一致,确认率超过99%。
- 整条染色体嵌合或片段嵌合结果在再次活检中确认率仅为15%-18%,提示嵌合体适合移植。
- 片段非整倍体确认率为56.6%,可能代表与嵌合胚胎不同的生物学病因。
核心结论
- PGTseq平台上整倍体或非整倍体结果与胚胎其余部分的倍性状态高度一致。
- 整条染色体嵌合和片段嵌合结果确认率较低,提示这些嵌合体适合胚胎移植。
- 片段非整倍体在胚胎中一致性率较高,可能代表与嵌合胚胎不同的生物学病因。
研究设计与样本
- 盲法前瞻性队列研究,共300枚囊胚被捐赠。
- 113枚胚胎为整倍体,163枚胚胎具有至少一条整条染色体非整倍体,24枚胚胎无整条染色体非整倍体但初始滋养外胚层活检具有至少一项次要发现。
- 所有囊胚均接受再次活检,并在PGTseq平台上进行非整倍体植入前遗传学检测。
主要发现
- 初始滋养外胚层活检为整倍体或整条染色体非整倍体的结果在再次活检样本中确认率超过99%。
- 整条染色体或片段嵌合的结果在后续再次活检中确认率为15%-18%。
- 片段非整倍体在再次活检样本中确认率为56.6%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine how often the results of a single trophectoderm (TE) biopsy tested by PGTseq, a targeted next-generation sequencing preimplantation genetic testing for aneuploidy technology, reflect the biology of the rest of the embryo. DESIGN: Blinded prospective cohort study. SETTING: University-affiliated private practice. PATIENT(S): A total of 300 blastocysts were donated; 113 of these embryos were euploid; 163 embryos possessed at least one whole chromosome aneuploidy; and 24 embryos were negative for whole chromosome aneuploidy but possessed at least one secondary finding on initial TE biopsy. INTERVENTION(S): All blastocysts underwent rebiopsy and preimplantation genetic testing for aneuploidy on the PGTseq platform. MAIN OUTCOME MEASURE(S): Partial concordance rate per embryo, total concordance rate per embryo, and total concordance rate per chromosomal event. RESULT(S): An initial TE biopsy result of euploidy or whole chromosome aneuploidy was reconfirmed in >99% of rebiopsied samples, affirming that meiotic errors are manifested in almost the entire embryo. In contrast, results of whole chromosome or segmental mosaicism were confirmed in 15%-18% of subsequent rebiopsies, suggesting that mitotic events are only sporadically seen throughout the embryo. Segmental aneuploidy was confirmed in 56.6% of rebiopsied samples, identifying a mixed meiotic and mitotic etiology for such abnormalities. CONCLUSION(S): A euploid or aneuploid result on the PGTseq platform is highly concordant with the rest of the embryo's ploidy status. The rarer confirmation of whole chromosome mosaic and segmental mosaic results suggest that these mosaics are suitable for embryo transfer. Segmental aneuploidy, with higher concordance rates throughout the embryo, may represent a different biologic etiology compared to mosaic embryos.
引用
- Kim J, Tao X, Cheng M, et al. The concordance rates of an initial trophectoderm biopsy with the rest of the embryo using PGTseq, a targeted next-generation sequencing platform for preimplantation genetic testing-aneuploidy. Fertil Steril. 2021. PMID: 34980428. doi:10.1016/j.fertnstert.2021.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。